[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for advanced breast cancer].
A phase II clinical study of 254-S, a new anticancer platinum complex for advanced breast cancer, was conducted by the 254-S Breast Cancer Study Group consisting of 6 institutions nation-wide. Considering the results of the phase I clinical study, 254-S was administered at 100 mg/m2 by intravenous drip infusion and this administration was repeated at least 2 times at 4-week intervals. Of 19 patients registered, 16 were evaluable for tumor response (complete cases). Partial response (PR) was obtained in 2 patients, for a 12.5% response rate. Major toxic effects observed were hematotoxicity thrombocytopenia and leukopenia, and gastrointestinal toxicity (nausea and vomiting, and anorexia), though there was no case in which the treatment with 254-S had to be discontinued due to the toxic effect.
Koyama
H
H
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
Ogawa
M
M
Kuraishi
Y
Y
Tominaga
K
K
Yoshida
M
M
Taguchi
T
T
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin